Press releases
- Bausch + Lomb Announces 2024 Annual Meeting of Shareholder Results
- Bausch + Lomb Announces Presentation of New Scientific Data and Evaluations Featuring Consumer, Vision Care and Pharmaceutical Products at Optometry’s Meeting®
- Bausch + Lomb Receives Health Canada Approval for enVista® Envy™* Full Visual Range Intraocular Lens
- Bausch + Lomb Announces First-Quarter 2024 Results
- Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting
- Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes
- Bausch + Lomb Reports More Than 84 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through Innovative Recycling Programs
- Bausch + Lomb Will Release First-Quarter 2024 Financial Results on May 1
- Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting
More ▼
Key statistics
On Friday, Bausch + Lomb Corp (BLCO:NYQ) closed at 15.34, 16.57% above the 52 week low of 13.16 set on May 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.44 |
---|---|
High | 15.50 |
Low | 15.28 |
Bid | 14.30 |
Offer | 15.87 |
Previous close | 15.39 |
Average volume | 329.62k |
---|---|
Shares outstanding | 351.52m |
Free float | 39.21m |
P/E (TTM) | -- |
Market cap | 5.39bn USD |
EPS (TTM) | -0.9603 USD |
Data delayed at least 15 minutes, as of Jun 01 2024 00:00 BST.
More ▼